[Federal Register Volume 59, Number 31 (Tuesday, February 15, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-3505]


[[Page Unknown]]

[Federal Register: February 15, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Co-Exclusive License: Type Alpha Platelet-
Derived Growth Factor (PDGF) Receptor Gene

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a co-exclusive world-wide license to practice the invention embodies in 
U.S. Patent Applications SN 07/308,282 and SN 07/915,884, both entitled 
``Type Alpha Platelet-Derived Growth Factor Receptor Gene'' to Targeted 
Genetics Corporation, of Seattle, Washington. The patent rights in this 
invention have been assigned to the United States of America.
    The prospective license will be royalty-bearing, will comply with 
the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7, and is 
expected to be co-exclusive with one other party, COR Therapeutics, 
Inc. It is anticipated that this license will be limited to gene 
therapy treatment of cardiovascular disease. Publication of this notice 
should be considered a modification of an earlier notice ``Prospective 
Grant of Exclusive License: Type Alpha Platelet-Derived Growth Factor'' 
(Vol. 58, No. 16, Wednesday, January 17, 1993, page 6287).
    This prospective co-exclusive license may be granted unless, within 
60 days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7. The patent application describes novel DNA segments that 
encode platelet-derived growth factor (PDGF) receptors that may be 
useful in therapies for conditions involving abnormal processes 
involving PDGF and its receptors. In particular, bioassay methods for 
detecting the expression of genes related to these DNA segments are 
effective in the identification of various classes of tumor cells, 
genetic defects in connective tissue growth, or in the healing 
response.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Mr. Steven M. Ferguson, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, Box OTT, Bethesda, MD 20892. Telephone: (301) 496-7735; 
Facsimile: (301) 402-0220. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by NIH within sixty (60) days of this notice 
will be considered.

    Dated: February 7, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-3505 Filed 2-14-94; 8:45 am]
BILLING CODE 4140-01-M